Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T)

被引：0

作者：

Cebon, Jonathan S.

Flaherty, Keith

Weber, Jeffrey S.

Kim, Kevin

Infante, Jeffrey R.

Daud, Adil

Hamid, Omid

Kefford, Richard

Schuchter, Lynn Mara

Sosman, Jeffrey Alan

Sznol, Mario

Sharfman, William Howard

Gonzalez, Rene

Andrews, Miles Cameron

Dronca, Roxana Stefania

Long, Georgina

Little, Shonda M.

Sun, Peng

Patel, Kiran

McWilliams, Robert R.

机构：

[1] Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia

[2] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA

[3] Comprehens Melanoma Res Ctr, Moffitt Canc Ctr, Tampa, FL USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA

[6] Univ Calif San Francisco, San Francisco, CA 94143 USA

[7] Angeles Clin & Res Inst, Los Angeles, CA USA

[8] Westmead Hosp, Westmead, NSW 2145, Australia

[9] Melanoma Inst Australia, Westmead, NSW, Australia

[10] Univ Penn, Philadelphia, PA 19104 USA

[11] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[12] Yale Univ, New Haven, CT USA

[13] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[14] Univ Colorado Denver, Aurora, CO USA

[15] Ludwig Inst Canc Res, Austin Branch, Heidelberg, Vic, Australia

[16] Mayo Clin, Dept Med Oncol, Rochester, MN USA

[17] Univ Sydney, Westmead Hosp, Melanoma Inst Australia, Sydney, NSW 2006, Australia

[18] GlaxoSmithKline, Collegeville, PA USA

[19] Mayo Clin, Rochester, MN USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9016

引用

页数：1